<code id='3CAD0C96BD'></code><style id='3CAD0C96BD'></style>
    • <acronym id='3CAD0C96BD'></acronym>
      <center id='3CAD0C96BD'><center id='3CAD0C96BD'><tfoot id='3CAD0C96BD'></tfoot></center><abbr id='3CAD0C96BD'><dir id='3CAD0C96BD'><tfoot id='3CAD0C96BD'></tfoot><noframes id='3CAD0C96BD'>

    • <optgroup id='3CAD0C96BD'><strike id='3CAD0C96BD'><sup id='3CAD0C96BD'></sup></strike><code id='3CAD0C96BD'></code></optgroup>
        1. <b id='3CAD0C96BD'><label id='3CAD0C96BD'><select id='3CAD0C96BD'><dt id='3CAD0C96BD'><span id='3CAD0C96BD'></span></dt></select></label></b><u id='3CAD0C96BD'></u>
          <i id='3CAD0C96BD'><strike id='3CAD0C96BD'><tt id='3CAD0C96BD'><pre id='3CAD0C96BD'></pre></tt></strike></i>

          entertainment

          entertainment

          author:comprehensive    Page View:9632
          Monica Bertagnolli -- health policy coverage from STAT
          NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

          WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

          “It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

          advertisement

          But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds
          Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

          AdobeTheFoodandDrugAdministrationsaidMondaythatithasdeepreservationsaboutNurOwn,aninvestigationalALS

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Biogen nominates mother of director’s child to replace him on board

          StevenSenn/APBiogen,abiotechgiantplaguedbyyearsofboardroomstrife,saidlateMondaythatthelongtimeandpol